Wednesday, July 25, 2012

Seeking Alpha: GlaxoSmithKline's R&D Is Delivering, But The Street's Not Buying

One of the less endearing, if not outright annoying, traits of those who make up Wall Street is their tendency to harp on whatever a company doesn't have at the moment. In the case of Big Pharma, good current quarterly results are often waved off with skepticism about generic competition and/or the pipeline. For GlaxoSmithKline (GSK) it looks like the reverse is true. Forget the solid pipeline and good recent Phase 3 results, it's this quarter's bad performance that somehow proves Glaxo isn't a good company.

Please read more here:
GlaxoSmithKline's R&D Is Delivering, But The Street's Not Buying

No comments: